Why the study?
Does standard-dose alteplase reduce the recurrence of ischemic stroke in patients with acute ischemic stroke compared to low-dose alteplase?
Population
501 patients with acute ischemic stroke (AIS) treated with intravenous thrombolysis with alteplase
Comparison
Standard-dose alteplase vs Low-dose alteplase
Design
Cohort
Follow-up
long-term
Authors
Loading...
Standard-dose alteplase was associated with lower long-term AIS recurrence risk; leaves open need for randomized confirmation before practice change.
Does standard-dose alteplase reduce the recurrence of ischemic stroke in patients with acute ischemic stroke compared to low-dose alteplase?
Standard-dose alteplase is associated with a reduced risk of long-term recurrence of acute ischemic stroke compared to low-dose alteplase, without affecting long-term mortality.
Zhai et al. (2023) studied this question.